Taheriazam Afshin, Bahador Reza, Karbasy Seyyed Hasan, Jamshidi Seyed Mir Mansoor Moazen, Torkaman Ali, Yahaghi Emad, Shakeri Mohammadreza
Department of Orthopedics Surgery, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran.
Department of Orthopaedic and Trauma Surgery, Birjand University of Medical Sciences, Birjand, Iran.
Diagn Pathol. 2015 Sep 17;10:166. doi: 10.1186/s13000-015-0400-3.
Osteosarcoma is the most common primary bone malignancy with high local aggressiveness and rapid metastasizing potential, resulting in poor survival. Increasing reports suggest that deregulated microRNAs (miRNAs) might provide novel therapeutic targets for cancers. However, the expression of miR-26a and miR-27a in osteosarcoma need further investigation in clinical samples. In our study, we evaluate the expression of these miRNAs in osteosarcoma tissues and compared with paired adjacent non-tumor bone tissues using RT-qPCR.
Total RNA was purified from patients with osteosarcoma and noncancerous bone tissues. Real-time PCR was applied to quantify the expression level of miR-26a and miR-27a. Moreover, the correlation of these markers with clinicopathological characteristics was also evaluated in osteosarcoma patients. A cox proportional hazards model was performed to assess multivariate analyses of prognostic values.
Our result suggested that miR-26aexpression level in osteosarcoma bone tissue was significantly lower than that in the paired noncancerous bone tissues. MiR-27a expression was higher in osteosarcoma bone tissue in comparison with paired noncancerous bone tissues. The results indicated that low expression level of miR-26a and high expression of miR-27a were associated with high TNM stage (P = 0.001; P = 0.012), tumor grade (P = 0.007; P = 0.016), and distant metastasis (P = 0.004; P = 0.001). Kaplan-Meier analysis and log-rank test indicated that patients with low expression of miR-26a and high expression of miR-27a had shorter overall survival (log-rank test: P < 0.001). Multivariate Cox proportional hazards model analysis showed that low expression of miR-26a and high expression of miR-27a (P = 0.021; P = 0.011), high TNM stage (P = 0.001; P = 0.003), tumor grade (P = 0.005; P = 0.01), and distant metastasis.(P = 0.002; P = 0.005) were independent prognostic factors for overall survival patients with osteosarcoma cancer.
In conclusion, our findings suggested that expression level of miR-26a and miR-27a contributes to aggressive progression of this malignancy. Therefore, may have clinical potentials as a non-invasive diagnostic/prognostic biomarker for osteosarcoma patients.
骨肉瘤是最常见的原发性骨恶性肿瘤,具有高度的局部侵袭性和快速转移的潜能,导致生存率较低。越来越多的报道表明,失调的微小RNA(miRNA)可能为癌症提供新的治疗靶点。然而,miR-26a和miR-27a在骨肉瘤中的表达在临床样本中仍需进一步研究。在我们的研究中,我们使用RT-qPCR评估了这些miRNA在骨肉瘤组织中的表达,并与配对的相邻非肿瘤骨组织进行了比较。
从骨肉瘤患者和非癌骨组织中纯化总RNA。应用实时PCR定量miR-26a和miR-27a的表达水平。此外,还评估了这些标志物与骨肉瘤患者临床病理特征的相关性。采用Cox比例风险模型进行预后价值的多因素分析。
我们的结果表明,骨肉瘤骨组织中miR-26a的表达水平显著低于配对的非癌骨组织。与配对的非癌骨组织相比,骨肉瘤骨组织中miR-27a的表达更高。结果表明,miR-26a低表达和miR-27a高表达与高TNM分期(P = 0.001;P = 0.012)、肿瘤分级(P = 0.007;P = 0.016)和远处转移(P = 0.004;P = 0.001)相关。Kaplan-Meier分析和对数秩检验表明,miR-26a低表达和miR-27a高表达的患者总生存期较短(对数秩检验:P < 0.001)。多因素Cox比例风险模型分析表明,miR-26a低表达和miR-27a高表达(P = 0.021;P = 0.011)、高TNM分期(P = 0.001;P = 0.003)、肿瘤分级(P = 0.005;P = 0.01)和远处转移(P = 0.002;P = 0.005)是骨肉瘤患者总生存期的独立预后因素。
总之,我们的研究结果表明,miR-26a和miR-27a的表达水平促进了这种恶性肿瘤的侵袭性进展。因此,它们可能具有作为骨肉瘤患者非侵入性诊断/预后生物标志物的临床潜力。